Key statistics
On Friday, Lipocine Inc (LPCN:NAQ) closed at 9.96, -19.48% below its 52-week high of 12.37, set on Jan 15, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 9.97 |
|---|---|
| High | 10.46 |
| Low | 9.61 |
| Bid | 8.79 |
| Offer | 9.97 |
| Previous close | 10.00 |
| Average volume | 140.88k |
|---|---|
| Shares outstanding | 5.55m |
| Free float | 5.39m |
| P/E (TTM) | -- |
| Market cap | 55.30m USD |
| EPS (TTM) | -1.04 USD |
Data delayed at least 15 minutes, as of Feb 27 2026 21:00 GMT.
More ▼
- Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
- Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
- Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
- Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
